Aspire Biopharma Holdings (ASBP) Other Accumulated Expenses (2022 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Other Accumulated Expenses for 5 consecutive years, with $353679.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses changed 0.0% year-over-year to $353679.0 in Q1 2026; TTM through Mar 2026 was $353679.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $353679.0, up 218.56% from the prior year.
• Other Accumulated Expenses was $353679.0 for Q1 2026 at Aspire Biopharma Holdings, roughly flat from $353679.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $353679.0 in Q1 2025 and troughed at $111026.0 in Q4 2024.
• A 5-year average of $266962.8 and a median of $283939.0 in 2024 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses plunged 53.53% in 2024 and surged 218.56% in 2025, its largest moves.
• Over 5 years, Other Accumulated Expenses stood at $122689.0 in 2022, then surged by 94.75% to $238939.0 in 2023, then sank by 53.53% to $111026.0 in 2024, then surged by 218.56% to $353679.0 in 2025, then changed by 0.0% to $353679.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $353679.0 (Q1 2026), $353679.0 (Q4 2025), and $353679.0 (Q3 2025), per Business Quant data.